Secondary prevention of stroke: can we do better than aspirin?

摘要

Meta-analyses have reported that antiplatelet therapy is associated with a 25% reduction in recurrent ischaemic stroke in patients with a previous stroke or transient ischaemic attack. Over the past few years, trials have assessed the efficacy and safety of antiplatelet drugs other than aspirin; one such drug is cilostazol, which inhibits the phosphodiesterase 3A enzyme and uptake of adenosine and has been shown to inhibit platelet aggregation.